Krishna Misra
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Krishna Misra has a total of 67 co-authors. Here are the top co-authors by number of shared publications:
- Durg Vijay Singh
Central University of South Bihar
7 shared publications - Anushree Tripathi
Department of Computer Science and Engineering, National Institute of Technology Patna, Patna, Bihar, India
4 shared publications Rajesh Kumar Kesharwani
Indian Institute of Information Technology
4 shared publicationsSangeeta Singh
Department of Applied Science, Indian Institute of Information Technology Allahabad, Prayagraj, India
4 shared publications- Shikha Agarwal
Central University of South Bihar
4 shared publications Sonali Mishra
Department of Applied Science and Bioinformatics, Indian Institute of Information Technology, Allahabad, 211012, India
4 shared publications
Latest Publications
- 22 April 2025
- Published by Bentham Science Publishers Ltd. in Current Computer-Aided Drug Design
- Vol. 21 (4) , 1-17
Targeting the Ubiquitin-conjugating Enzyme for Oral Squamous CellCarcinoma Therapy: Discovering Natural Inhibitors
Background: Oral Squamous Cell Carcinoma (OSCC) is a multiple-phase carcinogenic disease that concurrently involves malignant lesions, invasion, and metastasis. It has been reported that Ubiquitin-conjugating enzymes play a significant role in the progression of OSCC and other fatal cancers through the process of ubiquitination. Among them, UBE2D1 represents a promising target for therapeutic intervention. Strategies aimed at inhibiting UBE2D1 could restore the function of tumor suppressors, such as p53, and potentially enhance the effectiveness of existing cancer therapies. Objective: This study aims to discover the potential natural inhibitors of UBE2D1 from an extensive chemical library through computational techniques. Methods: This study utilized in silico methods, such as virtual screening, molecular docking, analysis of pharmacokinetic parameters, and molecular dynamics simulation, to discover the most effective inhibitors for the ubiquitin-conjugating enzyme. Results: Based on binding affinity, the top six compounds, ZINC15113777, ZINC225461658, ZINC107430641, ZINC259440, ZINC4025306, and ZINC107283931, were found to be the best for the selected target. Also, molecular dynamic simulation results showed that all these compounds form stable complexes with UBE2D1. Conclusion: Based on our analysis of the results, we have determined that natural products, specifically ZINC15113777, ZINC4025306, and ZINC107283931, have the ability to inhibit UBE2D1 efficiently and could be utilized as potential drugs for the treatment of OSCC and other cancers. Such approaches may help to reinstate normal apoptotic pathways and improve overall treatment outcomes in patients with cancers characterized by UBE2D1 dysregulation. Additionally, conducting in-vitro/vivo studies on these molecules could be a prospective avenue in the realm of pharmaceutical research.
- 22 April 2025
- Published by Bentham Science Publishers Ltd. in Current Computer-Aided Drug Design
- Vol. 21 (4) , 1-17
Targeting the Ubiquitin-conjugating Enzyme for Oral Squamous CellCarcinoma Therapy: Discovering Natural Inhibitors
Background: Oral Squamous Cell Carcinoma (OSCC) is a multiple-phase carcinogenic disease that concurrently involves malignant lesions, invasion, and metastasis. It has been reported that Ubiquitin-conjugating enzymes play a significant role in the progression of OSCC and other fatal cancers through the process of ubiquitination. Among them, UBE2D1 represents a promising target for therapeutic intervention. Strategies aimed at inhibiting UBE2D1 could restore the function of tumor suppressors, such as p53, and potentially enhance the effectiveness of existing cancer therapies. Objective: This study aims to discover the potential natural inhibitors of UBE2D1 from an extensive chemical library through computational techniques. Methods: This study utilized in silico methods, such as virtual screening, molecular docking, analysis of pharmacokinetic parameters, and molecular dynamics simulation, to discover the most effective inhibitors for the ubiquitin-conjugating enzyme. Results: Based on binding affinity, the top six compounds, ZINC15113777, ZINC225461658, ZINC107430641, ZINC259440, ZINC4025306, and ZINC107283931, were found to be the best for the selected target. Also, molecular dynamic simulation results showed that all these compounds form stable complexes with UBE2D1. Conclusion: Based on our analysis of the results, we have determined that natural products, specifically ZINC15113777, ZINC4025306, and ZINC107283931, have the ability to inhibit UBE2D1 efficiently and could be utilized as potential drugs for the treatment of OSCC and other cancers. Such approaches may help to reinstate normal apoptotic pathways and improve overall treatment outcomes in patients with cancers characterized by UBE2D1 dysregulation. Additionally, conducting in-vitro/vivo studies on these molecules could be a prospective avenue in the realm of pharmaceutical research.
- 14 February 2025
- Published by Springer Nature in 3 Biotech
- Vol. 15 (3) , 61
Exploring therapeutic potential of Bacopa monnieri bioactive compounds against Alzheimer’s and Parkinson’s diseases
Parkinson's disease (PD) and Alzheimer's disease (AD) consist of progressive illnesses of central nervous system that primarily affect the elderly and are characterized by movement symptoms, memory decline, and cognitive impairment. A number of variables, including the lack of a novel treatment, a steady rise in the patient population, and the high expense of care and treatment, have contributed to the growing significance of these diseases. In recent decades, we have gained a better understanding of the causes of diseases, but complex mechanisms of neuronal loss, combined with physiological factors that are incompatible, pose challenges in describing the pathogenic processes and devising effective treatments. Currently, there are no known treatments for most of these diseases, rendering them incurable. Therefore, there is a pressing need for therapeutic interventions that have the potential to effectively treat neurodegeneration. This study aimed to evaluate the efficacy of the ayurvedic herb Bacopa monnieri bioactive components against the therapeutic targets HTR1A, HTR1B, HTR2A, HTR2C, HTR7, alpha-synuclein, amyloid beta, and tau protein of Alzheimer's and Parkinson's illnesses. The docking analysis revealed the promising binding affinity with Quercetin, Apigenin, and Luteolin and Molecular mechanics/generalized Born surface area (MM/GBSA) further confirmed the stability of the complexes. In vitro investigation indicated that Quercetin is the most effective for treating AD and PD due to its considerable inhibition of alpha-synuclein production, whereas Luteolin is the favorable one for preventing both diseases by mitigating effects during Rotenone treatment. The future implications and constraints of the current study suggest that further validation in Invivo models of Alzheimer's and Parkinson's diseases is necessary to investigate the effects of Quercetin and Apigenin in the treatment of these conditions, as well as Luteolin and Quercetin for their prevention.
- 14 February 2025
- Published by Springer Nature in 3 Biotech
- Vol. 15 (3) , 61
Exploring therapeutic potential of Bacopa monnieri bioactive compounds against Alzheimer’s and Parkinson’s diseases
Parkinson's disease (PD) and Alzheimer's disease (AD) consist of progressive illnesses of central nervous system that primarily affect the elderly and are characterized by movement symptoms, memory decline, and cognitive impairment. A number of variables, including the lack of a novel treatment, a steady rise in the patient population, and the high expense of care and treatment, have contributed to the growing significance of these diseases. In recent decades, we have gained a better understanding of the causes of diseases, but complex mechanisms of neuronal loss, combined with physiological factors that are incompatible, pose challenges in describing the pathogenic processes and devising effective treatments. Currently, there are no known treatments for most of these diseases, rendering them incurable. Therefore, there is a pressing need for therapeutic interventions that have the potential to effectively treat neurodegeneration. This study aimed to evaluate the efficacy of the ayurvedic herb Bacopa monnieri bioactive components against the therapeutic targets HTR1A, HTR1B, HTR2A, HTR2C, HTR7, alpha-synuclein, amyloid beta, and tau protein of Alzheimer's and Parkinson's illnesses. The docking analysis revealed the promising binding affinity with Quercetin, Apigenin, and Luteolin and Molecular mechanics/generalized Born surface area (MM/GBSA) further confirmed the stability of the complexes. In vitro investigation indicated that Quercetin is the most effective for treating AD and PD due to its considerable inhibition of alpha-synuclein production, whereas Luteolin is the favorable one for preventing both diseases by mitigating effects during Rotenone treatment. The future implications and constraints of the current study suggest that further validation in Invivo models of Alzheimer's and Parkinson's diseases is necessary to investigate the effects of Quercetin and Apigenin in the treatment of these conditions, as well as Luteolin and Quercetin for their prevention.
- 11 March 2024
- Published by Springer Nature in Proceedings of the National Academy of Sciences, India Section B: Biological Sciences
- Vol. 94 (5) , 933-947
Remedial Measures for Neurodegenerative Diseases Targeting Gut-Microbial Dysfunction with Herbal Bio-Actives
- 11 March 2024
- Published by Springer Nature in Proceedings of the National Academy of Sciences, India Section B: Biological Sciences
- Vol. 94 (5) , 933-947
Remedial Measures for Neurodegenerative Diseases Targeting Gut-Microbial Dysfunction with Herbal Bio-Actives
- 13 December 2023
- Published by Taylor & Francis in Journal of Biomolecular Structure and Dynamics
- Vol. 43 (3) , 1459-1470
Anti-inflammatory effect of curcumin in an accelerated senescence model of Wistar rat: an in vivo and in-silico study
Curcumin, a biphenolic substance derived from turmeric (Curcuma longa), offers a number of health-beneficial effects, including anti-inflammatory, cardiovascular protection, anti-cancerous, and anti-angiogenic. By interacting with the PPAR gamma (Peroxisome Proliferator-Activated Receptor-gamma), curcumin inhibits NF-kappa B. These biological outcomes seem to be the outcome of NF-kappa B inhibition mediated by curcumin. The current study explores the in vivo impact of curcumin on several inflammatory parameters during aging in Wistar rats. An in-silico docking simulation study using Maestro and Desmond, Schrodinger, was carried out to further validate the experimental findings. According to our observation, rats given curcumin supplementation had a considerably (p <= 0.05) reduced level of inflammation. By generating numerous polar and hydrophobic interactions and exhibiting little conformational deviation throughout the simulation, in silico investigations showed that the proposed ligand curcumin had a high affinity for the enzyme COX-2. During simulation, protein-ligand complexes of curcumin with the other targets viz. 5-LOX, TNF-alpha and IL-6 also demonstrated improved binding and minimal fluctuation. The COX-2 and 5-LOX enzymes and the cytokines (TNF-alpha and IL-6) implicated in inflammation may have been inhibited by curcumin, highlighting its function as a multi-target inhibitor. Our study provides convincing support for the idea that eating a diet high in curcumin may help to reduce inflammation and help to explain some of its health-beneficial effects.Communicated by Ramaswamy H. Sarma
- 13 December 2023
- Published by Taylor & Francis in Journal of Biomolecular Structure and Dynamics
- Vol. 43 (3) , 1459-1470
Anti-inflammatory effect of curcumin in an accelerated senescence model of Wistar rat: an in vivo and in-silico study
Curcumin, a biphenolic substance derived from turmeric (Curcuma longa), offers a number of health-beneficial effects, including anti-inflammatory, cardiovascular protection, anti-cancerous, and anti-angiogenic. By interacting with the PPAR gamma (Peroxisome Proliferator-Activated Receptor-gamma), curcumin inhibits NF-kappa B. These biological outcomes seem to be the outcome of NF-kappa B inhibition mediated by curcumin. The current study explores the in vivo impact of curcumin on several inflammatory parameters during aging in Wistar rats. An in-silico docking simulation study using Maestro and Desmond, Schrodinger, was carried out to further validate the experimental findings. According to our observation, rats given curcumin supplementation had a considerably (p <= 0.05) reduced level of inflammation. By generating numerous polar and hydrophobic interactions and exhibiting little conformational deviation throughout the simulation, in silico investigations showed that the proposed ligand curcumin had a high affinity for the enzyme COX-2. During simulation, protein-ligand complexes of curcumin with the other targets viz. 5-LOX, TNF-alpha and IL-6 also demonstrated improved binding and minimal fluctuation. The COX-2 and 5-LOX enzymes and the cytokines (TNF-alpha and IL-6) implicated in inflammation may have been inhibited by curcumin, highlighting its function as a multi-target inhibitor. Our study provides convincing support for the idea that eating a diet high in curcumin may help to reduce inflammation and help to explain some of its health-beneficial effects.Communicated by Ramaswamy H. Sarma
- Open Access
- 15 June 2023
- Published by Qeios Ltd
Review of: "Natural Polyphenols of Pomegranate and Black Tea Juices can Combat COVID-19 through their SARS-CoV-2 3C-like Protease-inhibitory Activity"
The authors have just stated the use of polyphenols of pomegranate and black tea in combating Covid -19 as per literature reports. They have not given their own critical view how these polyphenols inhibit SARS-COV- 2 3C like protease activity. They...
- 15 June 2023
- Published by Qeios Ltd
Open AccessReview of: "Natural Polyphenols of Pomegranate and Black Tea Juices can Combat COVID-19 through their SARS-CoV-2 3C-like Protease-inhibitory Activity"
The authors have just stated the use of polyphenols of pomegranate and black tea in combating Covid -19 as per literature reports. They have not given their own critical view how these polyphenols inhibit SARS-COV- 2 3C like protease activity. They...
- 1 March 2023
- Published by Bentham Science Publishers Ltd. in Recent Patents on Biotechnology
- Vol. 17 (1) , 9-23
Artificial Intelligence in Accelerating Drug Discovery and Development
Drug discovery and development are critical processes that enable the treatment of wide variety of health-related problems. These are time-consuming, tedious, complicated, and costly processes. Numerous difficulties arise throughout the entire process of drug discovery, from design to testing. Corona Virus Disease 2019 (COVID-19) has recently posed a significant threat to global public health. SARS-Cov-2 and its variants are rapidly spreading in humans due to their high transmission rate. To effectively treat COVID-19, potential drugs and vaccines must be developed quickly. The advancement of artificial intelligence has shifted the focus of drug development away from traditional methods and toward bioinformatics tools. Computer-aided drug design techniques have demonstrated tremendous utility in dealing with massive amounts of biological data and developing efficient algorithms. Artificial intelligence enables more effective approaches to complex problems associated with drug discovery and development through the use of machine learning. Artificial intelligence-based technologies improve the pharmaceutical industry's ability to discover effective drugs. This review summarizes significant challenges encountered during the drug discovery and development processes, as well as the applications of artificial intelligence-based methods to overcome those obstacles in order to provide effective solutions to health problems. This may provide additional insight into the mechanism of action, resulting in the development of vaccines and potent substitutes for repurposed drugs that can be used to treat not only COVID-19 but also other ailments.
- 1 March 2023
- Published by Bentham Science Publishers Ltd. in Recent Patents on Biotechnology
- Vol. 17 (1) , 9-23
Artificial Intelligence in Accelerating Drug Discovery and Development
Drug discovery and development are critical processes that enable the treatment of wide variety of health-related problems. These are time-consuming, tedious, complicated, and costly processes. Numerous difficulties arise throughout the entire process of drug discovery, from design to testing. Corona Virus Disease 2019 (COVID-19) has recently posed a significant threat to global public health. SARS-Cov-2 and its variants are rapidly spreading in humans due to their high transmission rate. To effectively treat COVID-19, potential drugs and vaccines must be developed quickly. The advancement of artificial intelligence has shifted the focus of drug development away from traditional methods and toward bioinformatics tools. Computer-aided drug design techniques have demonstrated tremendous utility in dealing with massive amounts of biological data and developing efficient algorithms. Artificial intelligence enables more effective approaches to complex problems associated with drug discovery and development through the use of machine learning. Artificial intelligence-based technologies improve the pharmaceutical industry's ability to discover effective drugs. This review summarizes significant challenges encountered during the drug discovery and development processes, as well as the applications of artificial intelligence-based methods to overcome those obstacles in order to provide effective solutions to health problems. This may provide additional insight into the mechanism of action, resulting in the development of vaccines and potent substitutes for repurposed drugs that can be used to treat not only COVID-19 but also other ailments.
- 1 May 2022
- Published by Taylor & Francis in Journal of Biomolecular Structure and Dynamics
- Vol. 41 (10) , 4485-4503
Modulation of GPCR receptors common to gut inflammatory diseases and neuronal disorders, Alzheimer’s and Parkinson’s diseases as druggable targets through Withania somnifera bioactives: an in silico study
Microorganisms in human gastrointestinal tract have profound influence on the transformation of food into metabolites which can impact human health. Along with playing crucial roles in regulating and modulating various metabolic reactions and life processes, dysbiosis of gut microbiota also affects the permeability of gut and blood-brain barrier. This increases the chance of age-related neurological disorders’ like Alzheimer’s and Parkinson’s diseases. Withania somnifera (W. somnifera) has been proclaimed as a virtuous plant for the treatment of neurodegenerative diseases and many other problems. We have studied the bioactive components of W. somnifera for combined treatment of gut-dysbiosis led bowel diseases (Inflammatory Bowel Disease, Irritable Bowel Syndrome) and the most common neurodegenerative diseases through common potential targets. This approach can solve along with curing the neurodegenerative diseases, the factors causing these diseases would also be obstructed from entering the brain, consonantly curing Inflammatory Bowel Disease and Irritable Bowel Syndrome. Our work on GPCR receptors common to gut inflammatory diseases and neuronal disorders through Network Pharmacology, Molecular docking and Dynamic Simulation approach has shown that modulation of these receptors with bioactive compounds present in W. somnifera can result in effective control of these diseases. We have found five proteins (HTR1A, HTR1B, HTR2A, HTR2B & HTR7) and five best lead compounds (Withanolide A, B, E, Q & Anahygrine) against these targets after molecular docking analysis. Our simulation studies have finally shown that amongst these five HTR1A and HTR7 proteins are the best targets with the leads Withanolide E and Withanolide A against them, respectively. Communicated by Ramaswamy H. Sarma
- 1 May 2022
- Published by Taylor & Francis in Journal of Biomolecular Structure and Dynamics
- Vol. 41 (10) , 4485-4503
Modulation of GPCR receptors common to gut inflammatory diseases and neuronal disorders, Alzheimer’s and Parkinson’s diseases as druggable targets through Withania somnifera bioactives: an in silico study
Microorganisms in human gastrointestinal tract have profound influence on the transformation of food into metabolites which can impact human health. Along with playing crucial roles in regulating and modulating various metabolic reactions and life processes, dysbiosis of gut microbiota also affects the permeability of gut and blood-brain barrier. This increases the chance of age-related neurological disorders’ like Alzheimer’s and Parkinson’s diseases. Withania somnifera (W. somnifera) has been proclaimed as a virtuous plant for the treatment of neurodegenerative diseases and many other problems. We have studied the bioactive components of W. somnifera for combined treatment of gut-dysbiosis led bowel diseases (Inflammatory Bowel Disease, Irritable Bowel Syndrome) and the most common neurodegenerative diseases through common potential targets. This approach can solve along with curing the neurodegenerative diseases, the factors causing these diseases would also be obstructed from entering the brain, consonantly curing Inflammatory Bowel Disease and Irritable Bowel Syndrome. Our work on GPCR receptors common to gut inflammatory diseases and neuronal disorders through Network Pharmacology, Molecular docking and Dynamic Simulation approach has shown that modulation of these receptors with bioactive compounds present in W. somnifera can result in effective control of these diseases. We have found five proteins (HTR1A, HTR1B, HTR2A, HTR2B & HTR7) and five best lead compounds (Withanolide A, B, E, Q & Anahygrine) against these targets after molecular docking analysis. Our simulation studies have finally shown that amongst these five HTR1A and HTR7 proteins are the best targets with the leads Withanolide E and Withanolide A against them, respectively. Communicated by Ramaswamy H. Sarma
- 1 January 2022
- Published by Kare Publishing in Eurasian Journal of Medical Advances
- Vol. 2 (2) , 65-72
Nutraceutical Importance of Dietary Curcumin, Its Analogues in Restricting Melanoma Growth and Modulation of Multiple Targets
Objectives: Melanoma is one the most lethal form of skin cancer with a survival rate of less than 5% and thus possesses biggest challenge for its therapy among research scientists. The Melanoma progression within a tumor is guided by multiple mechanisms, thereby hindering the development of successful therapies. Therefore, there is a urgent demand to identify potential targets against melanoma cancer cells as well as to develop potent inhibitors in order to reduce melanoma at the very onset of cancer cell growth through targeting mutidrug resistance. It is well reported that curcumin is acting as inhibitor for metastasis of melanoma cancer cells. The most potential target of melanoma cancer cells has to be identified in order to reduce the relapse as well as to overcome multidrug drug resistance. Methods: In this study, the potency of curcumin analogues as well as their interaction with potential targets was identified by insilico approaches.Their efficacy has been examined through invitro assay. Results: Based on both invitro and insilico studies, few curcumin analogues have shown higher inhibitory activity against melanoma cancer cells than curcumin. Conclusion: The present study predicts some novel curcumin analogues that can act as potent inhibitor of melanoma cancer cells.
- 1 January 2022
- Published by Kare Publishing in Eurasian Journal of Medical Advances
- Vol. 2 (2) , 65-72
Nutraceutical Importance of Dietary Curcumin, Its Analogues in Restricting Melanoma Growth and Modulation of Multiple Targets
Objectives: Melanoma is one the most lethal form of skin cancer with a survival rate of less than 5% and thus possesses biggest challenge for its therapy among research scientists. The Melanoma progression within a tumor is guided by multiple mechanisms, thereby hindering the development of successful therapies. Therefore, there is a urgent demand to identify potential targets against melanoma cancer cells as well as to develop potent inhibitors in order to reduce melanoma at the very onset of cancer cell growth through targeting mutidrug resistance. It is well reported that curcumin is acting as inhibitor for metastasis of melanoma cancer cells. The most potential target of melanoma cancer cells has to be identified in order to reduce the relapse as well as to overcome multidrug drug resistance. Methods: In this study, the potency of curcumin analogues as well as their interaction with potential targets was identified by insilico approaches.Their efficacy has been examined through invitro assay. Results: Based on both invitro and insilico studies, few curcumin analogues have shown higher inhibitory activity against melanoma cancer cells than curcumin. Conclusion: The present study predicts some novel curcumin analogues that can act as potent inhibitor of melanoma cancer cells.
- 13 August 2019
- Published by Springer Nature in Molecular Biology Reports
- Vol. 46 (6) , 5805-5820
Controlling pathogenesis in Candida albicans by targeting Efg1 and Glyoxylate pathway through naturally occurring polyphenols
Candida albicans has frequently shown resistance to azoles, the commonly used antifungal drugs. Efg1 has dual role under normoxia and hypoxia supporting infection. It is the major regulator of morphogenesis in C. albicans requisite for its pathogenesis. Targeting this protein is expected to render Candida ineffective to undergo filamentation causing virulence. Further the glyoxylate pathway supports the stress resistance and pathogenesis. In the present study an in silico approach and in vitro validation has been performed to find the potential role of polyphenols in controlling hyphal growth in C. albicans. The aspect of changes biome which may provide required niche to the pathogen has been checked which certainly opens the doors towards safe natural polyphenol-based drugs as potent antifungals.
- 13 August 2019
- Published by Springer Nature in Molecular Biology Reports
- Vol. 46 (6) , 5805-5820
Controlling pathogenesis in Candida albicans by targeting Efg1 and Glyoxylate pathway through naturally occurring polyphenols
Candida albicans has frequently shown resistance to azoles, the commonly used antifungal drugs. Efg1 has dual role under normoxia and hypoxia supporting infection. It is the major regulator of morphogenesis in C. albicans requisite for its pathogenesis. Targeting this protein is expected to render Candida ineffective to undergo filamentation causing virulence. Further the glyoxylate pathway supports the stress resistance and pathogenesis. In the present study an in silico approach and in vitro validation has been performed to find the potential role of polyphenols in controlling hyphal growth in C. albicans. The aspect of changes biome which may provide required niche to the pathogen has been checked which certainly opens the doors towards safe natural polyphenol-based drugs as potent antifungals.